Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02859857 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Study of BXQ-350 in Adult Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by Bexion Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 86
- Enrollment target
NCT02859857: Completed Phase 1 study, sponsored by Bexion Pharmaceuticals.
NCT02859857 is a Phase 1 study that has completed, run by Bexion Pharmaceuticals. The registered enrollment target is 86 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (43% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02859857, a Phase 1 study, has completed, sponsored by Bexion Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 86 participants
- Enrollment target
Study Summary
The objective of this study is to characterize the safety profile and determine the maximum tolerate dose (MTD) of BXQ-350, when given as a single agent at escalating doses, according to the investigational product (IP) related dose-limiting toxicities (DLTs) in patients with advanced solid tumors. Secondarily to assess the preliminary antitumor activity of BXQ-350 in solid tumors and recurrent high grade gliomas.
Primary Outcome
· To determine the maximum tolerate dose (MTD) of BXQ-350, when given as a single agent at escalating doses, according to the investigational product (IP) related dose-limiting toxicities (DLTs) in patients with advanced solid tumors
Interventions
- DRUG BXQ-350
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2016-09-01 |
| Est. Completion | 2020-06-15 |
| Phase | Phase 1 |
What the finished NCT02859857 record still lists
NCT02859857 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 86 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (43% higher).
The record links to 0 conditions, and to 1 intervention - of which BXQ-350 is the first listed.
NCT02859857 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02859857 about?
NCT02859857 is a clinical study titled "Phase 1 Study of BXQ-350 in Adult Patients With Advanced Solid Tumors". The objective of this study is to characterize the safety profile and determine the maximum tolerate dose (MTD) of BXQ-350, when given as a single agent at escalating doses, according to the investigational product (IP) related dose-limiting toxicities (DLTs) in patients with advanced solid tumors. ...
What is the current status of trial NCT02859857?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 86 participants. The study started on 2016-09-01. Estimated completion is 2020-06-15.
What interventions are being tested in trial NCT02859857?
The interventions under investigation include: BXQ-350 (DRUG).
Who is sponsoring clinical trial NCT02859857?
This trial is sponsored by Bexion Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02859857's enrollment target sits among peer trials
86 652nd of 2000 higher than 1,345 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01639508 · 86 participants · Phase 2
Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity
- NCT03519269 · 86 participants · NA
Navio Robotic Versus Conventional Total Knee Arthroplasty
- NCT04132999 · 86 participants · NA
PAP for Children With DS and OSAS
- NCT04545957 · 86 participants · NA
Jump: MR Simulation For Radiation Therapy Master Protocol
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI